Drug: Blinatumomab (Blincyto, Amgen)
Status: Supplemental biologics license application (sBLA) approved, converting accelerated approval to full approval for relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in adults and children
Significant Information:
- Blinatumomab—CD19-directed CD3 bispecific T-cell engager—is the first and only immunotherapy to yield overall survival (OS) superior to that of standard -of –care (SOC) chemotherapy in this